RUNX3 and cancer: Meanwhile, ex vivo studies of cytotoxic CD4+ T cells from human cancer patients points to variable overexpression of either TBX21 or RUNX3 plus BLIMP-1 (via PRDM1) when compared with non-cytotoxic CD4+ T cells.